洞察市场格局
解锁药品研发情报

免费客服电话

18983288589
试用企业版

首页 临床进展 Which score to predict diabetes remission?

【ChiCTR2100043429】Which score to predict diabetes remission?

查看原文
立即下载
基本信息
登记号

ChiCTR2100043429

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2021-02-17

临床申请受理号

/

靶点

/

适应症

diabetes

试验通俗题目

Which score to predict diabetes remission?

试验专业题目

Predicting diabetes remission after bariatric surgery: Which score should we use?

申办单位信息
申请人联系人
申请人名称
联系人邮箱
联系人邮编

联系人通讯地址
临床试验信息
试验目的

To validate the performance of available risk prediction scores for diabetes remission 1 year after surgical treatment and determine optimal model.

试验分类
试验类型

连续入组

试验分期

回顾性研究

随机化

As the design of the study is retrospective and comprises only one group, the randomization procedure was not required.

盲法

N/A

试验项目经费来源

The study required no funding

试验范围

/

目标入组人数

252

实际入组人数

/

第一例入组时间

2019-10-22

试验终止时间

2020-06-10

是否属于一致性

/

入选标准

We included consecutive patients with T2DM who underwent bariatric surgery, eighter laparoscopic sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) in our hospital and completed 1 year of postoperative follow-up.；

排除标准

Patients with already existing severe complications of T2DM, type 1 diabetes mellitus as well as history of bariatric surgery and those who were qualified for reoperation were excluded from the study.；

研究者信息
研究负责人姓名
试验机构

The study required no funding

研究负责人电话
研究负责人邮箱
研究负责人邮编

/

联系人通讯地址
<END>

The study required no funding的其他临床试验

更多

波兰2nd Department of General Surgery, Jagiellonian University Medical College, Kraków, Poland.的其他临床试验

更多

最新临床资讯

更多
对摩熵医药数据库感兴趣，可以免费体验产品
体验产品

同适应症药物临床试验

更多